Please ensure Javascript is enabled for purposes of website accessibility

If This Is Millennials' Favorite Stock, I Feel Sorry for Them

By Sean Williams – Updated Apr 15, 2019 at 4:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The younger generation really fancies this marijuana stock.

The marijuana industry is budding before our eyes. Last year, Canada became the first industrialized country in the world to give the green light to recreational marijuana, validating the industry's business model and demonstrating that legal cannabis will be here for many decades to come.

To Canada's south, we've now seen two-thirds of all U.S. states legalize marijuana in some capacity, with 10 states allowing for legal adult consumption. To boot, the Food and Drug Administration approved its very first cannabis-derived drug, and President Trump signed the Farm Bill into law in December, legalizing hemp and hemp-based cannabidiol products.

An up-close look at a flowering cannabis plant in an indoor greenhouse.

Image source: Getty Images.

Millennials' favorite stock is...a marijuana company?

Although it's an industry that'll find consumers of all ages, support for the cannabis industry primarily comes from the younger generation. I'm looking at you, millennials.

Back in April 2018, the independent Quinnipiac University conducted a study and found that 63% of respondents favored legalizing pot nationwide. However, support for legalization was just 43% for seniors aged 65 and up, and 63% for those aged 50 to 64. Comparably, 82% of millennials aged 18 to 34 were in favor of legalization. 

But what you may not realize is just how enamored millennials really are with marijuana. Markets Insider, a division of Business Insider, reported this past week that more people own shares of Aurora Cannabis (ACB -2.40%) than Apple on Robinhood, a free trading app that's particularly popular among millennials.

According to Markets Insider data, 247,157 Robinhood users own shares of Aurora Cannabis in their accounts, up 20,000 from the previous week. Meanwhile, Apple, which had held the top position for almost three months, fell to second with 237,050 shareholders. For added context, Aurora Cannabis was only the 22nd most popular stock on Robinhood in October, when Aurora Cannabis uplisted from the over-the-counter exchange to the New York Stock Exchange. 

A cannabis leaf lying atop carbonation in a glass, with pot leaves off to the right of the glass.

Image source: Getty Images.

Here's why millennials are infatuated with Aurora Cannabis

Why Aurora Cannabis?

To begin with, it's on track to be the largest producer of cannabis once it's running on all cylinders. Currently producing at an annual run rate of 100,000 kilograms a year, the company has suggested it's capable of producing more than 500,000 kilos at its peak. However, this language was used prior to the completion of its ICC Labs acquisition in South America, which added 92,000 square feet of existing capacity and approximately 1.1 million square feet of under-construction greenhouses. In my view, around 700,000 kilograms at its peak is more likely. As a top-producing grower, Aurora should attract plenty of long-term supply deals.

The company also looks ripe for a partnership. In September, it was reported that Coca-Cola (KO -0.97%) was in discussion with Aurora to either make an equity investment or forge a joint venture. Coca-Cola isn't oblivious to the fact that cannabidiol-infused beverages could be a hot commodity throughout North America in the years to come, and finding a large partner is pertinent to reaching this market. Ultimately, Coca-Cola walked away without a deal and has suggested it'll be monitoring the industry from the sidelines. But if Aurora was drawing interest from Coca-Cola, a partnership with a brand-name beverage company is coming probably sooner than later.

Aurora Cannabis also has breadth and product diversity on its side. It has a presence in close to two dozen countries and is actively working on moving beyond its reliance on dried cannabis flower. It's introduced a line of softgel capsules, intends to enter the infused beverage market later this year (when Canada gives alternative consumption options the green light), and has plans to enter the U.S. hemp market in the months to come. These alternative cannabis products are the key to higher operating margins.

A frustrated millennial investor putting his hands up in disgust as he looks at his laptop.

Image source: Getty Images.

Millennials have chosen...poorly

So, millennials have chosen a surefire winner, right? Well, not exactly. To be honest, I feel pretty bad for millennials if they're choosing Aurora Cannabis over thousands of other potential investments.

Since the beginning of 2018, Aurora Cannabis' market cap has increased by a whopping 138%. This is the result of it purchasing CanniMed Therapeutics for $852 million, acquiring MedReleaf for $2.5 billion, and buying ICC Labs for $221 million. But the company's share price has declined by 3% over that same time frame -- an underperformance of 141 percentage points. How does a gap this large get created? The simple answer is share-based dilution.

Until recently, Canadian pot stocks had little to no access to basic banking services. This meant no nondilutive forms of financing, such as lines of credit or loans. Needing cash to expand their growing capacity and finance acquisitions, most marijuana stocks turned to bought-deal offerings. This is where common stock, convertible debentures, stock options, and/or warrants are sold to raise capital. The good news is that issuing shares has been successful in raising capital for the industry. The bad news is that it's crushed shareholders, as is evidenced in this instance.

Because Aurora Cannabis is contending with persistent net cash outflows, it's relied on issuing stock to cover its acquisitions, as well as, in large part, to fund its operational expansion. With the exception of a small cash component in the CanniMed deal, all of its other big acquisitions have been financed by issuing shares. In less than five years, the company's outstanding share count has ballooned from 16 million to what'll likely be 1 billion-plus within the next quarter or two. This type of dilution is killing investor value, and it'll have a largely negative impact on earnings per share.

Check out all our earnings call transcripts.

Even if Aurora Cannabis is able to generate an operating profit in the quarters to come, its ballooning share count will ensure that it translates into a not-so-meaningful earnings-per-share figure. It could take years before Aurora Cannabis is valued at a forward price-to-earnings ratio that's even remotely palatable to fundamentally focused investors.

Needless to say, this investor believes millennials could be sorely disappointed with their favorite stock.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Apple. The Motley Fool has the following options: long January 2020 $150 calls on Apple and short January 2020 $155 calls on Apple. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurora Cannabis Stock Quote
Aurora Cannabis
$1.22 (-2.40%) $0.03
The Coca-Cola Company Stock Quote
The Coca-Cola Company
$56.02 (-0.97%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.